Ophthalmology Times Europe Newsletter

To view this email as a web page, click here.

Rho kinase inhibitors getting to the heart of the matter

Rho kinase inhibitors—the newest drugs introduced for treating glaucoma—"get to the heart of the matter” by targeting specific glaucomatous abnormalities, such as trabecular meshwork outflow, said Yvonne Ou, MD.

The future: Artificial intelligence gains acceptance in ophthalmology

Artificial intelligence (AI) is a technology in which machines and equipment can “learn” from experience and adjust accordingly.

This woman had *what* living in her eye?!

Every now and then we catch wind of a seemingly implausible eye-related story, but here's one that really threw us for a loop.

Submicron formula ‘step forward’ in steroid therapy

Case study: Complex retinal detachment in presumed genetic vitreoretinopathy

Managing unique challenges of pediatric congenital cataract

An international encyclopedic database for IOL specifications

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.